Are you a community physician treating patients with multiple myeloma?

If so, this workshop is for you!

Because of the limited experience with T cell redirection treatment strategies in the real world and especially bispecific T cell engagers and CAR T therapies among oncologists and health care professionals outside CAR T administering centers, there is a gap in the understanding, management and utilization of these therapies in patients that might benefit from these types of treatments. As more drug products become available through commercial and research routes, there will be a greater need  for a close partnership between the centers where these treatments are administered and the smaller community centers where the vast majority of oncology patients are typically followed and receive the bulk of their treatments. There is an urgent need to bridge this knowledge gap and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers and CAR T therapies among health care professionals.

Mark your calendars for the 23rd IMS Annual Meeting in Glasgow, Scotland.

The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects. This year’s program includes:

• Four thematic sessions:
  • Newly Diagnosed Multiple Myeloma
  • How to Treat First Relapse
  • Blood-Based Technology for Diagnosis and Monitoring
  • Monitoring Immune System and Preventing Infections and Adverse Effects
• Talks and symposia led by key opinion leaders in the myeloma community
• Keynote addresses
• Joint sessions with regulatory agencies and other organizations
• Meet the Expert sessions
• Oral Abstracts (Basic Biology, Preclinical Trials, Clinical Studies)
• Poster presentations and discussion sessions

Program

Save the date for the 8th Immune Effector Cell Therapies in Multiple Myeloma Workshop – March 19-20, 2027.

More details will be released soon!